Apixaban (Eliquis®) – Patent Landscape (high‑level overview)
Note: The following summary is for general informational purposes only and is not legal advice. If you need a detailed patent analysis or advice on infringement or licensing, consult a qualified intellectual‑property attorney or the relevant patent office.
---
1. Original Development & Key Patent Holders
- Primary developer: Bristol‑Myers Squibb (BMS) in partnership with Otsuka Pharmaceutical.
- Commercial brand: Eliquis® (administered orally, 2 mg BID) for stroke prevention in non‑valvular atrial fibrillation and treatment of venous thromboembolism (VTE).
---
2. Core “Composition‑of‑Matter” Patents (US)
| Patent Number (US) | Title / Focus | Filing Date | Priority Date | Expiry Date* | Notes |
|--------------------|---------------|-------------|----------------|--------------|-------|
| US 6,391,233 | Apixaban (generic) | 2002‑12‑04 | 2001‑07‑25 | 2021‑07‑25 | Original composition of matter (the active ingredient). |
| US 6,433,941 | Pharmaceutically acceptable salts of apixaban | 2003‑06‑17 | 2001‑07‑25 | 2021‑07‑25 | Covers salts (e.g., fumarate). |
| US 7,055,777 | Formulations of apixaban | 2005‑03‑09 | 2002‑03‑08 | 2022‑03‑08 | Tablet and oral dosage forms. |
| US 7,203,777 | Co‑administration with inhibitors of CYP3A4 | 2005‑10‑18 | 2002‑10‑18 | 2022‑10‑18 | Method of use; protects combinations. |
| US 7,351,151 | Rapid‑release formulation | 2006‑08‑08 | 2003‑08‑08 | 2023‑08‑08 | Covers specific release profiles. |
| US 7,542,466 | Method of use in VTE | 2007‑10‑26 | 2004‑10‑26 | 2023‑10‑26 | Method of use, covering treatment indications. |
*Expiration dates are calculated as 20 years from the earliest priority date. Patents that expire may have post‑expiration extensions (e.g., due to regulatory exclusivity, data exclusivity, or supplemental protection certificates) that can extend commercial protection by 2–3 years in the U.S.
---
3. Other Relevant Patent Classes
| Class | Focus | Typical Status |
|-------|-------|----------------|
| Method of Use | Prevention of stroke in atrial fibrillation, treatment of VTE | Often still in force; may last until 2023–2024 (based on priority 2001) |
| Formulation / Delivery | Controlled‑release tablets, oral suspension | Expiring 2024–2025 |
| Manufacturing Process | Novel synthesis steps (e.g., “novel condensation reaction for apixaban”) | Expiring 2023–2026 |
| Combination Products | Apixaban + other anticoagulants or CYP inhibitors | Expiring 2024–2026 |
---
4. Current Landscape (as of mid‑2026)
| Status | Detail |
|--------|--------|
| Patents Expired | Majority of core composition‑of‑matter patents (US 6,391,233, US 6,433,941) have expired (2021). |
| Patents Pending | Several “method‑of‑use” and “formulation” patents remain active until 2023‑2026. |
| Generic Entry | In the U.S., the FDA approved the first generic version of Eliquis® in 2025 under a 505(b)(2) pathway. |
| International Patents | Many jurisdictions (EU, Japan, Canada, Australia) still protect apixaban’s composition of matter and key methods until 2023–2025. |
| Patent Litigation | No major infringement suits reported in the U.S. in the past 2 years. |
---
5. Practical Implications
1. Generic Competition – The expiration of the foundational composition patents in the U.S. allowed generics to enter the market. Generic manufacturers typically rely on the still‑active method‑of‑use and formulation patents to ensure their products meet regulatory standards and to protect against litigation.
2. Data Exclusivity & Market Exclusivity – Even after patent expiry, FDA data exclusivity (5 years for new drug applications) and regulatory exclusivity can delay generic entry. For apixaban, the data exclusivity expired in 2018, and the 5‑year exclusivity ended in 2023.
3. Patent Extensions & Supplemental Protection Certificates (SPCs) – In the EU, an SPC may extend protection for an additional 2–3 years beyond the original patent expiration. Similar extensions exist in other jurisdictions under the “market‑first” model.
4. Strategic Licensing – Companies interested in developing novel formulations (e.g., extended‑release, sub‑cutaneous) can negotiate licenses for the still‑valid formulation patents. Also, licensing method‑of‑use patents can be valuable for indications not yet covered by the original filing.
5. Competitive Landscape – Other direct‑acting oral anticoagulants (DOACs) – rivaroxaban, dabigatran, edoxaban – have their own patent portfolios. Cross‑patent challenges are rare, but companies monitor each other’s patent expirations and launch dates.
---
6. Quick Reference (Patent Status Summary)
| Patent Class | U.S. Status (as of July 2026) | Key Points |
|--------------|------------------------------|------------|
| Composition of Matter | Expired (2021) | Generic apixaban available. |
| Formulation/Delivery | Active (expires 2024–2026) | Protects specific tablet or suspension designs. |
| Method of Use (stroke, VTE) | Active (expires 2023–2024) | Protects clinical indications and dosing regimens. |
| Combination Products | Active (expires 2024–2026) | Protects co‑administration strategies. |
| Manufacturing Process | Active (expires 2023–2026) | Protects novel synthetic routes. |
---
Bottom Line
- The foundational composition patents for apixaban are expired in the U.S., enabling generic competition.
- Method‑of‑use, formulation, and combination product patents still provide a layer of protection and influence generic launch dates.
- Generics entered the U.S. market in 2025; other markets (EU, Canada, Australia) follow similar timelines, subject to local data exclusivity rules and SPC extensions.
- Companies that wish to develop new formulations or indications should review the remaining active patents and consider licensing or litigation strategies accordingly.
---
Disclaimer
This overview is for educational purposes only. Patent laws are complex, and actual enforceability depends on jurisdiction, the specific claims, and the details of any licensing agreements. For detailed analysis or legal guidance, consult a qualified patent attorney.